It’s no secret that Clovis Oncology is up against some serious marketing muscle in the PARP inhibitor arena. And investors are doubting the company’s ability to hang in there. More: Clovis investors lose faith as Rubraca struggles against Big Pharma's
read moreSince Shire Korea CEO took on the new Takeda Korea CEO job during the merger, the reorganization process has favored the Shire employees, a Takeda union has complained, in contrast to management’s recent “minimal” changes comment. More: Takeda staffers accuse
read moreFujifilm has sealed the deal. With the completion of an $890 million, all-cash exchange with Biogen, the CDMO is now in possession of a biologics production facility in Denmark with about 800 employees. More: Fujifilm pays Biogen nearly B for Denmark
read morePresident Donald Trump and Democratic presidential candidate Bernie Sanders amplified calls for drug importation this week, putting pharma on defense. And the chatter is only getting louder ahead of next year’s elections. More: Longtime pharma critic and Democratic candidate Sanders
read moreVas Narasimhan had held top jobs at Novartis before taking the reins last year. He’d handled big challenges, too, including an H1N1 vaccine shortage during a pandemic. But as he notes in an NYT interview, he wasn’t prepared for the
read moreBempegaldesleukin, Nektar’s lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist. More: FDA grants Opdivo combo Breakthrough Designation for melanoma Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals